Geoffrey R. Oxnard, MD

Drs. Camidge and Oxnard discuss novel EGFR inhibitors, the role of precision medicine in early cancer detection, and balancing clinical and industry roles.

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, Dana-Farber Cancer Institute, discusses RET fusions in non–small cell lung cancer.

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the potential impact of implementing cell-free DNA tests as a method to detect signs of early stage cancer.

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cancer Genome Atlas (CCGA) study in an interview with OncLive during the 2018 ASCO Annual Meeting.

Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of osimertinib (Tagrisso) in the TATTON trial for patients with lung cancer.

Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses resistance mechanisms that occur in patients with EGFR-positive T790M non

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.